Interpace Biosciences Bilan de santé
Santé financière contrôle des critères 2/6
Interpace Biosciences has a total shareholder equity of $-12.5M and total debt of $6.8M, which brings its debt-to-equity ratio to -54.3%. Its total assets and total liabilities are $13.0M and $25.5M respectively. Interpace Biosciences's EBIT is $4.4M making its interest coverage ratio 5. It has cash and short-term investments of $2.0M.
Informations clés
-54.3%
Ratio d'endettement
US$6.78m
Dette
| Ratio de couverture des intérêts | 5x |
| Argent liquide | US$2.02m |
| Fonds propres | -US$12.49m |
| Total du passif | US$25.46m |
| Total des actifs | US$12.97m |
Mises à jour récentes de la santé financière
Analyse de la situation financière
Passif à court terme: IDXG has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Passif à long terme: IDXG has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Historique et analyse du ratio d'endettement
Niveau d'endettement: IDXG has negative shareholder equity, which is a more serious situation than a high debt level.
Réduire la dette: IDXG's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Couverture de la dette: IDXG's debt is well covered by operating cash flow (52.9%).
Couverture des intérêts: IDXG's interest payments on its debt are well covered by EBIT (5x coverage).